Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arikayce in Cystic Fibrosis with Pseudomonas Aeruginosa
NCT01316276Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Oct 2012
- Primary completion
- Jul 2015
- Countries
- 17
01
Overview
Phase 3, open-label trial of amikacin liposome inhalation suspension in cystic fibrosis (CF) and Pseudomonas aeruginosa infection, sponsored by Insmed Incorporated. Primary endpoints: Treatment Emergent Adverse Events at 672 days and Laboratory Abnormalities at 672 days. Started Oct 2012; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT01316276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01316276.